MWM
NMRA icon

Meridian Wealth Management’s Neumora Therapeutics NMRA Stock Holding History

Meridian Wealth Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Sell
94,400
-8,000
-8% -$15.2K ﹤0.01% 805
2026
Q1 		$200K Buy
102,400
+16,000
+19% +$41.5K 0.01% 752
2025
Q4 		$155K Buy
86,400
+27,000
+45% +$59.1K 0.01% 733
2025
Q3 		$108K Buy
+59,400
New +$96K ﹤0.01% 693

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Meridian Wealth Management's NMRA Position: Q2 2026 in Review

Meridian Wealth Management reduced its Neumora Therapeutics (NMRA) stake by 7.8% in Q2 2026, selling an estimated $15.2K and leaving 94,400 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #805.

Meridian Wealth Management first reported a position in NMRA in Q3 2025 and has held it in 4 quarters since. The position peaked at $200K in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Meridian Wealth Management held 94,400 shares of Neumora Therapeutics worth $160K as of Q2 2026.
  • Meridian Wealth Management sold 8,000 Neumora Therapeutics shares in Q2 2026, an estimated $15.2K.
  • Neumora Therapeutics made up ﹤0.01% of Meridian Wealth Management's portfolio in Q2 2026, its #805 holding.
  • Meridian Wealth Management first reported a position in Neumora Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Meridian Wealth Management's Neumora Therapeutics position peaked at $200K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Meridian Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.